Checkpoint Therapeutics Azioni (NASDAQ: CKPT)

Ultime notizie per Checkpoint Therapeutics (NASDAQ:CKPT) Azioni

CHECKPOINT THERAPEUTICS INC

Checkpoint Therapeutics

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics Inc

Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) reported quarterly losses of $(0.14) per share. This is a 99.47 percent increase over losses of $(26.23) per share from the same period last year. The company reported $316.00 thousand in sales this quarter. This is a 15.70K percent increase over sales of $2.00 thousand the same period last year.

Earnings

News

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Reported May 8, 2025: Faraday Future Q1 EPS $(0.14) Up From $(26.23) YoY, Sales $316.00K Up From $2.00K YoY

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 5.35% on an annualized basis producing an average annual return of 15.62%. Currently, Guidewire Software has a market capitalization of $17.91 billion. 
Buying $100 In GWRE: If an investor had bought $100 of GWRE stock 10 years ago, it would be worth $411.90 today based on a price of $213.57 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746832511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

GWRE

$100 Invested In Guidewire Software 10 Years Ago Would Be Worth This Much Today

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $54 to $45.

Price Target

Analyst Ratings

RCKT

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $45

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and lowers the price target from $28 to $25.

FDMT

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

UBS analyst Trung Huynh maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $44 to $38.

CLDX

UBS Maintains Buy on Celldex Therapeutics, Lowers Price Target to $38

Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) has outperformed the market over the past 20 years by 8.79% on an annualized basis producing an average annual return of 16.95%. Currently, Domino's Pizza has a market capitalization of $16.40 billion. 
Buying $1000 In DPZ: If an investor had bought $1000 of DPZ stock 20 years ago, it would be worth $22,913.88 today based on a price of $478.90 for DPZ at the time of writing.
<h3>Domino's Pizza's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746829811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Domino's Pizza 20 Years Ago Would Be Worth Today

UBS analyst Christopher Schoell maintains Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy and lowers the price target from $102 to $75.

CCOI

UBS Maintains Buy on Cogent Comms Hldgs, Lowers Price Target to $75

UBS analyst Josh Silverstein maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Buy and lowers the price target from $32 to $30.

CTRA

UBS Maintains Buy on Coterra Energy, Lowers Price Target to $30

UBS analyst Steven Fisher maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Buy and lowers the price target from $154 to $152.

UBS Maintains Buy on Jacobs Solutions, Lowers Price Target to $152

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $110 to $109.

INSM

UBS Maintains Buy on Insmed, Lowers Price Target to $109

UBS analyst Peter Grom maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and lowers the price target from $63 to $59.

UBS Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $59

UBS analyst Dan Leonard maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and lowers the price target from $95 to $70.

TECH

UBS Maintains Buy on Bio-Techne, Lowers Price Target to $70

UBS analyst John Lovallo maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Neutral and lowers the price target from $74 to $72.

TREX

UBS Maintains Neutral on Trex Co, Lowers Price Target to $72

UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $27 to $25.

XRAY

UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $25

UBS analyst Kunal Madhukar maintains ZipRecruiter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) with a Neutral and lowers the price target from $7 to $6.

UBS Maintains Neutral on ZipRecruiter, Lowers Price Target to $6

UBS analyst Seth Gilbert maintains Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Neutral and lowers the price target from $3.5 to $2.

VERI

UBS Maintains Neutral on Veritone, Lowers Price Target to $2

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) with a Neutral and lowers the price target from $10 to $8.6.

TMCI

UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $8.6

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 2.1% on an annualized basis producing an average annual return of 12.37%. Currently, UnitedHealth Group has a market capitalization of $344.73 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 10 years ago, it would be worth $3,285.34 today based on a price of $380.02 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746828911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years

UBS analyst Kevin Mcveigh maintains Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) with a Neutral and lowers the price target from $2.95 to $1.9.

UBS Maintains Neutral on Rackspace Technology, Lowers Price Target to $1.9

UBS analyst Chris Zhang maintains International Money (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMXI#NASDAQ">IMXI</a>) with a Neutral and lowers the price target from $17 to $12.

IMXI

UBS Maintains Neutral on International Money, Lowers Price Target to $12

Legal

Press Releases

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options

CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT

Comments

Checkpoint Therapeutics

Notizie

Ultime notizie per Checkpoint Therapeutics (NASDAQ:CKPT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO